Preface Peter M.A. Calverley This preface, my first as the Chief Editor of the ERS Monograph, gives me an opportunity to do two important things. First, to thank the European Respiratory Society (ERS) for appointing me to this role, which is an exciting challenge. Second, to thank my predecessor Professor John R. Hurst for all his hard work with the Monograph. John’s enthusiasm and vision allowed the Monograph to flourish my task, together with our newly appointed Deputy Chief Editor Christian B. Laursen, is to ensure the Monograph continues to do so. We have plans about how we can make the Monograph even better, but our core mission will not change – namely, to provide up-to-date, authoritative overviews of topics relevant to all who work in respiratory medicine. Although each issue of the Monograph is produced on a very rapid timescale for a book of its size, there is inevitably an overlap between work commissioned by one Editor and the next. This is true of this latest issue on Lung Diseases and Cancer, which reflects the hard work of John and his colleagues and especially of the Guest Editors – Miguel Ángel Martínez-García, Mina Gaga and Kwun M. Fong. This issue provides a complimentary approach to many discussions of cancer and the lung, and explores the common causal pathways of cancer and lung disease, as well as the many ways in which they interact to influence the management of patients. The distinguished international experts who have contributed provide the reader with insights that range from basic disease mechanisms, through epidemiology and lung conditions predisposing to cancer, to the impact of lung disease on cancer outcomes and treatment. This kind of information is hard to come by in more conventional publications and shows how the Monograph provides data relevant to clinical practice that cannot be easily found elsewhere. So please enjoy this stimulating and wide-ranging review of a very important topic. Disclosures: P.M.A. Calverley reports receiving grants, personal fees and non-financial support from pharmaceutical companies that make medicines to treat respiratory disease. This includes reimbursement for educational activities and advisory work, and support to attend meetings. Copyright ©ERS 2022. Print ISBN: 978-1-84984-154-2. Online ISBN: 978-1-84984-155-9. Print ISSN: 2312-508X. Online ISSN: 2312-5098. https://doi.org/10.1183/2312508X.10023522 vii